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Abstract
Background: Cutaneous Malignant Melanoma is an aggressive form of skin cancer, arising in cutaneous melanocytes. The
transcription factor PAX3 regulates melanocyte specification from neural crest cells during development but expression in
differentiated melanocytes is uncertain. By contrast it is frequently found in melanomas and naevi and is a marker for
melanoma staging and detection. In this study we analysed the expression of PAX3 across the spectrum of melanocytic
cells, from normal melanocytes to cells of benign and malignant lesions to better assess its function in these various tissues.
Pax3 and PAX3 (italicized) refer to the mouse and human gene, respectively; whereas Pax3 and PAX3 (non-italicized) refer to
the corresponding mouse and human protein.
Methodology and Principal Findings: PAX3 expression was analysed by immunohistochemistry and qRT-PCR.
Immunofluorescence was used for co-expression with differentiation, migration and survival markers. As expected PAX3
expression was observed in naevi and melanoma cells. It was also found in melanocytes of normal skin where it co-
expressed with melanocyte markers, MITF and MLANA. Co-expression with its downstream target, antiapoptotic factor
BCL2L1 confirms PAX3 as a cell survival regulator. PAX3 was also co-expressed with melanoma cell migration marker MCAM
in dermal naevi and melanoma cell nests, but this downstream target of PAX3 was not present in normal epidermal
melanocytes, suggesting differential roles for PAX3 in normal epidermal melanocytes and melanoma cells. Most
interestingly, a proportion of PAX3-positive epidermal melanocytes in normal skin show HES1 and Ki67 co-expression,
indicating their less differentiated proliferative phenotype.
Conclusions and Significance: Our results suggest that a previously identified role for PAX3, that of regulator of an
undifferentiated plastic state, may operate in melanocytes of normal skin. This role, possibly required for cellular response to
environmental stimuli, may contribute to formation and development of melanocytic lesions in which PAX3 expression is
prominent.
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Introduction
Cutaneous Malignant Melanoma is a highly aggressive form of
skin cancer, thought to be derived from cutaneous melanocytes or
melanoblasts. Its aggressiveness is attributed to frequent metastasis
and high drug resistance. Intensive research into the mechanisms
regulating melanoma tumourigenesis has included investigation of
the factors and pathways of normal melanocyte development and
function. One key factor that regulates melanocyte development
from neural crest derived progenitor cells is the transcriptional
factor PAX3.
PAX3 is very frequently expressed in melanomas and naevi [1–6].
In fact, PAX3 has been identified as a significant marker for
melanoma staging [7,8] and for detection of circulating melanoma
cells [7]. It has also been identified as an immunogenic protein in
melanomas [9–11], with several epitopes able to induce the host’s
immune response - stimulation of the immune response against PAX3-
expressing tumour cells results in tumour growth suppression [9,11].
PAX3 is a member of the PAX family of transcription factors
which are highly conserved throughout phylogeny. All play a
crucial role in embryogenesis but are also implicated in
tumourigenesis [12–18]. Although PAX3 is recognised as a key
embryonic regulator of melanocyte specification and development,
its expression and function in differentiated epidermal melanocytes
of adult human skin is largely unexplored and its role in melanoma
remains unclear [19].
Pax3 starts its expression in early embryos, in neural crest
precursor cells that later give rise to melanocyte precursors,
melanoblasts [19–24]. Here the main function of Pax3 besides
neural crest specification is regulation of melanoblast survival and
proliferation [23,25]. Together with SRY (sex determining region
Y)-box 10 (Sox10), Pax3 regulates expression of key melanocyte
specification factor Microphthalmia-associated transcription factor (Mitf).
It has been suggested that Pax3 controls a ‘‘nodal point’’ in
melanocyte differentiation; it simultaneously activates Mitf and
represses Dopachrome-tautomerase (Dct) transcription thus blocking
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threshold this repression is removed, allowing Mitf, in the presence
of b-catenin, to activate Dct expression and melanocyte matura-
tion. This model of regulation of melanocyte differentiation
suggests that Pax3 expression is either negligible or significantly
reduced in adult differentiated melanocytes.
Several studies report PAX3 expression in naevi and melanomas
[2,4], and show no expression in melanocytes of normal skin [5,6],
thus concluding that PAX3 re-expression might be involved in
melanocyte transformation. In contrast to this widely accepted
assumption, other studies note PAX3 expression in melanocytes of
normal skin [22,27], and more specifically its up-regulation as a
result of the UV-induced loss of TGFb signalling from
keratinocytes [28]. Additionally, PAX3 expression has been
described in cultured melanocytes [3,29] and melanoblasts with
no significant change in levels of either mRNA or protein between
these two cell types [29].
Here we confirm that PAX3 is present in the majority of naevus
and melanoma cells. We also show conclusively that PAX3 is
expressed in melanocytes of normal skin where it is co-expressed
with known melanocyte markers. Since the precise role played by
PAX3 in melanomas is not clear, we have looked into potential
PAX3 regulated pathways within normal melanocytes. We have
chosen pathway-representative markers that are also downstream
targets of PAX3 and analysed their co-expression with PAX3 in
normal skin melanocytes, naevi and melanomas. Interestingly,
while the majority of PAX3-positive melanocytes in the epidermis
of normal skin show a mature phenotype, a portion (around 20%)
show a less differentiated and proliferative phenotype. Moreover,
PAX3-positive melanocytes frequently show expression of BCL2-
like 1 (BCL2L1, also known as Bcl-X, bcl-xL or BCL-XL/S), an
antiapoptotic marker. Taken together these results indicate that
melanocytes of normal skin display a phenotype that is
predisposed to malignant transformation (antiapoptotic, undiffer-
entiated and proliferative). We also show that PAX3- positive
epidermal melanocytes of normal skin are molecularly distinct
from those of the hair follicle, which like melanoma cells express
Melanoma cell adhesion molecule (MCAM, also known as
MUC18/CD146), associated with cell migration and melanoma
progression and metastasis.
Results
PAX3 expression in normal skin, naevi and melanoma
PAX3 expression was analysed by immunohistochemistry in
tissue sections from paraffin embedded samples of normal skin,
naevus, primary melanoma and melanoma metastases. Positive
staining for PAX3 was obtained after performing heat-induced
antigen retrieval in an EDTA/Tris buffer, pH 8.0 and incubating
the primary antibody (anti-PAX3, DSHB) at room temperature
(Figure 1A, top panel). Antigen retrieval using the most common
10mM citrate buffer, pH 6.0 with the same staining protocol,
failed to produce a positive signal in several of these samples, and
in those that were positive after citrate antigen retrieval, the
intensity of staining was dramatically reduced. Negative controls
included omitting the primary antibody from the procedure
resulting in no immunohistochemical signal (not shown). Mouse
monoclonal anti-PAX3 antibody (DSHB) has been previously
confirmed by immunohistochemistry to be specific for the PAX3
protein [30]. PAX3-specific staining was also confirmed using a
different commercially available anti-PAX3 antibody (Invitrogen)
(Figure 2, A–C and E). However, we have observed less intensive
staining overall with this polyclonal antibody (Invitrogen),
compared to that observed with the monoclonal (DSHB).
All of the samples analysed showed positive PAX3 staining in
more than 10% of cells (Figure 1A, top panel). In normal skin
PAX3-positive cells showed a pattern of distribution that is
characteristic of melanocytes; i.e. they were found at the
epidermal-dermal boundary and along the hair follicle
(Figure 1A–D). When adjacent sections were stained with MITF,
a known marker of melanocytes, a comparable pattern of
distribution was observed (Figure 1A, bottom panel).
The intensity of PAX3 staining varied between cells within the
same lesion and between different samples. There was no obvious
correlation between either intensity or number of PAX3-positive
cells and lesion type. However, PAX3-positive cells of normal skin
samples generally showed weaker staining and far fewer cells were
positive, compared to those in naevi and primary melanoma
samples. In contrast, melanoma metastases have an overall low
level of PAX3 expression and these cells were mainly located at the
periphery of the lesion.
Additional analysis by quantitative RT-PCR was performed on
a separate set of samples, to confirm PAX3 expression in normal
skin, naevi, primary melanomas, and melanoma metastases. PAX3
expression was detected in all naevi (5/5), primary melanomas (5/
5) and melanoma metastases analysed (5/5), and in one out of two
(1/2) normal skin samples. The highest levels of PAX3 expression
were found in melanoma metastases (mean fold change of
258361198), followed by naevi and primary melanomas with
101639 and 73655- fold change, respectively (Figure 1E). Even
though these results suggest that PAX3 might be up-regulated in
advanced melanomas (melanoma metastases vs. primary melano-
mas) comparison with immunohistochemistry results show that
expression levels are not due to increased amounts of PAX3 per
individual cell, but rather they reflect the number of cells
expressing PAX3 (Figure 1A). Nevertheless RT-PCR results
confirm PAX3 expression in melanocytes of normal skin.
Characterisation of PAX3-positive cells: Co-expression of
PAX3 and MITF
In order to validate PAX3 expression in naevi and melanomas
as well as to confirm that PAX3-positive cells in normal skin are in
fact melanocytes, co-staining of PAX3 and MITF was assessed by
immunofluorescence. Indeed, in all of the samples analysed,
including normal skin, PAX3-positive cells co-express MITF
(Figure 2, A–C and E). However, in normal skin (as in other
samples) a small number of cells showed only MITF and not
PAX3 expression, highlighting the variation in normal melanocyte
cell phenotype.
In normal skin samples 81.6% of all MITF-positive melanocytes
were also PAX3-positive (Figure 2D). Both naevi and primary
melanoma samples show similar numbers of MITF-positive cells
that also express PAX3 (97.2% and 94.5%, respectively)
(Figure 2D). Interestingly, melanoma metastases show significantly
less PAX3-positive than MITF-positive cells (Figure 2D), and
generally these were weakly stained for PAX3. However, this was
observed primarily when using rabbit polyclonal antibody to
PAX3 (Invitrogen) for immunofluorescent staining. When the
mouse monoclonal anti-PAX3 antibody (DSHB) was used for
immunohistochemistry staining, many more PAX3-positive cells
were observed on the same sample. The discrepancy between
these two results is probably due to the sensitivity of the two
antibodies. Nevertheless, the intensity of PAX3 staining in
individual cells within the same tissue sample varied when either
antibody was used, whereas MITF levels were uniform across each
sample (Figure 2, A–C). This is shown clearly in cells of the A2058
metastatic cell line (Figure 2C) and may reflect differential cell
status/phenotype.
PAX3 in Melanocytes
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PAX3 with MITF, HES1 and MLANA
Even though the overall percentage of MITF-positive melano-
cytes that were also PAX3-positive in normal skin was not
significantly different in either benign or malignant melanocytic
lesions (Figure 2D), the distribution of cells that co-expressed
PAX3 and MITF differed between the epidermis and hair follicles
of normal skin. Around 90% of MITF-positive melanocytes in the
epidermis and the outer root sheath (ORS) of the hair follicle were
PAX3-positive, compared to only 65% of those in the bulbar area
(Figure 3D). Interestingly there was a distinct location in the hair
bulb, at the very base of the hair, populated exclusively by MITF-
positive melanocytes (Figure 2E).
Given this difference between epidermal and follicular melano-
cytes, we thought it necessary to further characterise PAX3-
positive melanocytes in the normal skin. We therefore co-stained
PAX3 cells with Hairy and enhancer of split 1 (HES1) (Figure 3A
and 4A–C) or Melan-A (MLANA, also known as MART-1)
(Figure 3B and 4D, E), markers of a less or more differentiated cell
Figure 1. PAX3 expression in melanocytic and melanoma cells. A) Immunohistochemistry shows PAX3 expression (top panel) in
representative samples of normal skin, naevus, primary melanoma and melanoma metastasis, compared to MITF expression in adjacent sections
(bottom panel). B–D) Show the distribution of PAX3-positive melanocytes (arrowheads) in normal skin: along the hair follicle (early (B) and late (C)
anagen); and in the epidermis (D). Arrows in (D) point to the cytoplasmic melanin deposit distinguishable from the nuclear PAX3 staining
(arrowheads). Asterisk in (B) and (C) marks a dermal papilla. PAX3 was labelled with mouse monoclonal antibody (DSHB). E) PAX3 expression was
analysed by RT-PCR and the graph shows the mean fold increase of PAX3 expression in naevi, primary melanomas and lymph node metastases
normalised to the expression in normal skin.
doi:10.1371/journal.pone.0009977.g001
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double-labelled cells we found that HES1 was expressed in a
proportion of PAX3-positive melanocytes, while cells that were
only HES1-positive were identified as keratinocytes [31,32]
(Figure 3A). The number of PAX3-positive melanocytes co-
expressing HES1 was lowest in the matrix of the hair bulb (10.5%),
Figure 2. Co-expression of PAX3 and MITF in melanocytic and melanoma cells. A–C) Double immunofluorescent staining showing co-
expression of PAX3 and MITF in: (A) the epidermal melanocytes of normal skin; (B) primary melanoma; and (C) in an A2058 metastatic melanoma cell
line. Arrowheads in (A) show PAX3-positive normal epidermal melanocytes. Lines in (A) and (B) demarcate epidermal-dermal border (EDB). The
variable PAX3 expression was clearly visible in the A2058 cell line (C). For all these experiments depicted in the figure, PAX3 was labelled with rabbit
polyclonal antibody (Invitrogen). D) Graph showing the overall number of MITF and PAX3 double labelled cells in normal skins, naevi, primary
melanomas and melanoma metastases. Each column represents a percentage of MITF-positive cells that are also PAX3-positive averaged across all
samples. E) Double immunofluorescent staining shows PAX3 and MITF co-expressing melanocytes (yellow-orange) in the bulb of the hair follicle of
normal skin. Note the single MITF-labelled melanocytes (green) at the base of the hair.
doi:10.1371/journal.pone.0009977.g002
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(Figure 3D). By contrast, MLANA was expressed in more that
60% of both epidermal and ORS PAX3-positive melanocytes,
compared to 36% of those in the matrix of the hair bulb
(Figure 3D). We have also observed a significant number of single
MLANA-labelled melanocytes (Figure 3B) (30.5% in the epider-
mis, 3.9% in ORS, and 40% in the hair bulb).
This indicates that melanocytes, both follicular and epidermal,
have a variable differentiation status: from less differentiated
PAX3, MITF and HES1-positive to more differentiated PAX3,
MITF and MLANA-positive. The observed PAX3-negative,
MLANA-positive epidermal melanocytes may represent mature
terminally differentiated melanocytes.
In addition, Yang and colleagues [28] have recently proposed
that in UV-treated skin TGF-b signalling from keratinocytes is
downregulated, which increases PAX3 expression in epidermal
melanocytes and stimulates their proliferation. In order to check if
PAX3-positive melanocytes observed here are proliferating we co-
stained PAX3 with a marker of proliferation, Ki67, and found
18.1% of epidermal melanocytes in samples of sun-exposed skin
(scalp) to be double-labelled (Figure 3C). In contrast to this, in
samples that had relatively little sun exposure (breast) one single
double labelled cell was observed in the epidermis (accounting for
1.4% of PAX3-positive cells).
PAX3 in cell survival: Co-expression with BCL2L1
To further characterise the phenotype of PAX3-positive
melanocytes relative to melanoma cells, expression of an
antiapoptotic factor BCL2L1 was assessed in PAX3-positive cells
(Figure 5A). We have observed that a similar proportion of PAX3-
positive cells were also BCL2L1-positive in melanocytes of normal
skin, in naevi and in melanoma cells in all of the samples analysed
(Figure 5D). The exception is melanoma metastases, in which
BCL2L1 was detected in only one sample (out of four) and both
PAX3 and BCL2L1 were weakly stained and very rarely co-stain.
BCL2L1 expression in epidermal keratinocytes, as reported
previously [33], served as an internal positive control for the
staining.
BCL2L1 expression in normal PAX3-positive melanocytes
indicates that they might utilise the same cell survival regulatory
mechanism as melanoma cells, in order to sustain continuous
renewal in the ever-changing environment of the epidermis. It is
possible that one of the roles PAX3 plays in adult melanocytes
(similar to that in development) is to ensure their maintenance and
survival, while regulating their specification and proliferation.
PAX3 in cell migration: Co-expression with MCAM
Expression of the melanoma progression marker MCAM was
also analysed relative to PAX3. MCAM expression was observed
in most naevi and melanoma samples analysed; 80% (4/5) naevi
samples, 66.7% (4/6) primary melanomas and 100% (5/5) of
melanoma metastases. There was no MCAM expression in
epidermal melanocytes of normal skin (Figure 5B). Notably we
frequently observed MCAM expression in hair follicle cells of
normal skin [34–36], mainly in the ORS and not exclusively in
melanocytic cells (Figure 5C). MCAM expression in the
endothelial cells of the blood vessels served as an internal positive
control [36,37].
In naevi samples MCAM expression was observed in specific
areas, mainly in nests of cells in the dermal component of the
naevus and only a small proportion (14.7%) of PAX3-positive cells
were MCAM-positive (Figure 5B, E). Compared to naevi, primary
melanomas showed MCAM expression in a larger proportion of
PAX3-positive cells, 56.4% (Figure 5B, E), which are again
primarily located in the dermal component of the lesion. Samples
of melanoma metastases showed MCAM expression in the
majority (93.2%) of PAX3-positive cells (Figure 5B, E).
In general, MCAM co-expressed with PAX3 in all MCAM-
positive samples. In accordance with previous reports [34], the
number of MCAM expressing PAX3-positive cells increased with
malignant and particularly metastatic transformation. The expres-
sion of MCAM in follicular melanocytes, in contrast to the absence
of expression in epidermal melanocytes, highlights again the
difference between these two melanocyte populations.
Figure 3. Co-expression analysis of PAX3-positive epidermal
melanocytes of normal skin. Epidermal melanocytes of normal skin
show a variable differentiation status: less differentiated melanocytes
co-expressing PAX3 (mouse monoclonal antibody, DSHB) and HES1 (A);
more differentiated co-expressing PAX3 (rabbit polyclonal, Invitrogen)
and MLANA (B); and mature melanocytes expressing only MLANA (B).
Single HES1-labelled cells in the epidermis are keratinocytes (A). C)
PAX3 (mouse monoclonal antibody, DSHB) and Ki67 co-expressing
melanocytes are also observed in the epidermis of sun-exposed skin.
Lines in (A), (B) and (C) demarcate the epidermal-dermal border (EDB) or
epidermal surface (ES). D) Graph shows the distribution of differenti-
ation marker expression in normal skin melanocytes with respect to
melanocyte location (in epidermis, outer root sheath (ORS), or hair
follicle bulb).
doi:10.1371/journal.pone.0009977.g003
PAX3 in Melanocytes
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PAX3 expression in normal skin, naevi and melanoma
In agreement with previous reports, we confirm here that PAX3
is expressed in all melanoma and naevi samples analysed. There is
however a paucity of studies analysing PAX3 expression in
differentiated melanocytes in human skin. Traditionally consid-
ered a critical embryonic regulator, PAX3 has been suggested to
maintain melanocyte stem cells in the bulge area of the hair
follicles in mice [26], but was thought to be down-regulated upon
terminal differentiation of melanocytes. This belief has been
supported by reports detailing the absence of PAX3 expression in
melanocytes of normal human skin in contrast to naevi and
melanomas [5,6]. Our results show conclusively that PAX3 is
expressed in both epidermal and follicular melanocytes of human
skin. Furthermore, co-expression with MITF confirms the
melanocytic origin of these PAX3-positive cells. We also show
here, for the first time, the variable phenotype of epidermal
melanocytes of normal skin.
The observed frequency of PAX3 expression in naevi,
melanomas and specifically in melanocytes in normal skin is
much higher than reported elsewhere [5,6]. One possible
explanation could be the methodology we used, namely EDTA/
Tris antigen retrieval buffer, rather than the citrate buffer
commonly used by other researchers, which was, in our
experience, less efficient. It might also reflect the influence of
environmental factors, namely sun exposure and solar radiation. It
has recently been suggested that in UV-treated skin TGF-b
signalling from keratinocytes is down-regulated, increasing PAX3
expression in epidermal melanocytes thus stimulating their
proliferation [28]. All the samples used in this study are collected
from people living in Australia, where the solar radiation levels are
in the high to extreme range for much of the year. A recent report
from New Zealand [27] shows PAX3 expression in all naevi,
melanomas and normal skin samples, confirming our findings.
Further studies are required to investigate differences in PAX3
expression in skin samples derived from the Southern vs. the
Northern hemispheres.
Normal skin samples used in this study, mainly originating
from anatomic locations frequently exposed to the sun (such as
limbs and face), were free of any melanocytic lesion having been
used for other diagnostic purposes. We have included here two
normal skin samples from breast reductions which would have
lower sun exposure levels and these samples also show PAX3-
positive melanocytes in the epidermis. We have looked to see if
PAX3-positive melanocytes in our samples were proliferative, by
co-staining with Ki67. In our samples of sun-exposed skin, 18.1%
of epidermal PAX3-positive melanocytes were proliferative, but
the majority were not. This was in contrast to samples subjected
to low levels of sun exposure, where we observed one single
PAX3, Ki67-positive cell. However, to accurately address the
question whether the high frequency of PAX3 expression in
normal melanocytes observed in this study, relative to previously
published papers, is caused in any way by the extent of sun
exposure, a more thorough analysis of skin subjected to chronic
and/or acute UV exposure relative to sun-protected skin, would
need to be performed.
Figure 4. Co-expression analysis of PAX3-positive follicular
melanocytes. A) The transverse section of the hair follicle shows both
PAX3 and HES1 co-expressing (enlarged in B), and single PAX3-
expressing (enlarged in C), melanocytes in the outer root sheath (ORS).
The line circumscribes the hair follicle. PAX3 was labelled with mouse
monoclonal antibody (DSHB). D) The longitudinal section of the hair
follicle shows PAX3 and MLANA co-expressing (enlarged in the insert on
the left) and single PAX3-expressing (enlarged in the insert on the right)
melanocytes in the outer root sheath (ORS). E) Single PAX3-expresing
(arrows) and PAX3 and MLANA co-expressing (arrowheads) melano-
cytes in the matrix of the hair bulb. PAX3 was labelled with rabbit
polyclonal antibody (Invitrogen).
doi:10.1371/journal.pone.0009977.g004
PAX3 in Melanocytes
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role in regulating differentiation
PAX3 and MITF are crucial regulators of melanocyte
development and not surprisingly have overlapping expression.
To some extent they lie on opposing sides of the differentiation
pathway, PAX3 being upstream of MITF and MITF initiating the
melanogenic cascade and differentiation. We were interested to
see if there is an association between expression of PAX3 and
MITF (indicated by their co-expression) and the stage of
melanocyte differentiation (based on the cell location, mainly in
the hair follicle), but found no correlation. Studies on mice and
human skin both show the existence of skin stem cells in the lower
permanent portion of the hair follicle, or bulge [35,38,39]. It is
reported that mouse bulge melanocyte stem cells are PAX3-
positive and MITF-negative [40]; however no reports confirm this
to be the case in human skin. In this study we were not able to find
such cells. Instead the majority of melanocytes we observed, both
in the epidermis and the outer root sheath of the hair follicle, were
PAX3 and MITF-positive. In contrast to this, the matrix of the
hair bulb has far fewer PAX3 and MITF-positive melanocytes and
the base of the hair comprises solely MITF-positive (PAX3-
negative) melanocytes. Similarly, the number of PAX3, MLANA-
double-labelled melanocytes in the epidermis and ORS were
around 60%, but were much lower (around 36%) in the hair
matrix. This would indicate that some epidermal melanocytes
resemble more the undifferentiated transient amplifying cells of the
growing hair rather than differentiated cells of the hair matrix.
On the other side of differentiation is the transcription factor
HES1, suggested to prevent premature differentiation of melano-
cytes. Hes1 is reported to be a mediator of Notch signalling in skin
development and in hair follicle maintenance where it regulates
commitment of epidermal keratinocytes to terminal differentiation
[32,41]. Hes1 is expressed in spinous layers and mediates spinous
cell gene induction and thus terminal differentiation of epidermal
keratinocytes [32]. In a mature hair follicle it is most prominent in
the inner root sheath, in matrix cells committed to terminally
differentiate to form the hair shaft [31,32]. On the other hand, in
the melanocytic lineage, Notch signalling, acting through Hes1,
plays a crucial role in survival of immature melanoblasts and
melanocyte stem cells, by preventing initiation of apoptosis [42].
Figure 5. Co-expression of PAX3 with markers of cell survival and migration in melanocytic and melanoma cells. A) Double
immunofluorescent staining showing PAX3 (mouse monoclonal antibody, DSHB) and BCL2L1 co-expression in representative samples of normal skin,
naevus, primary melanoma and melanoma metastasis. B) PAX3 (mouse monoclonal antibody, DSHB) and MCAM co-expression in normal skin
(epidermal melanocytes), naevus, primary melanoma and melanoma metastasis. Lines in (A) and (B) demarcate the epidermal-dermal border (EDB) or
epidermal surface (ES). C) In contrast to the epidermal melanocytes, some PAX3-positive melanocytes in the outer root sheath (ORS) co-express
MCAM. D) Graph showing the overall number of PAX3, BCL2L1 double-labelled cells in normal skins, naevi, primary melanomas and melanoma
metastases. Each column represents a percentage of PAX3-positive cells that are also BCL2L1-positive, averaged across all samples. E) Graph showing
the overall number of PAX3, MCAM double-labelled cells in normal skins, naevi, primary melanomas and melanoma metastases. Each column
represents a percentage of PAX3-positive cells that are also MCAM-positive, averaged across all samples.
doi:10.1371/journal.pone.0009977.g005
PAX3 in Melanocytes
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nocyte stem cells before they reach the hair bulb and regulates
their proper location in the ORS and in the hair matrix [43].
Therefore it is not surprising that we see a decrease in the number
of PAX3 and HES1-positive cells in the hair bulb compared to the
ORS (10.5% and 23.7%, respectively). What is surprising is that
around 28% of PAX3-positive epidermal melanocytes are also
HES1-positive, indicating they are not terminally differentiated.
In summary, it seems that epidermal melanocytes are not all
terminally differentiated and similar to those in the hair follicle,
they exhibit variable differentiation status with persistent PAX3
expression. Melanocytes in the ORS of the hair follicle are mostly
PAX3 and MITF-positive and not all are fully differentiated
(23.7% HES1-positive, 61.5% MLANA-positive). In the matrix of
the hair bulb the number of PAX3-positive melanocytes is lower
(around 65%), with only a small proportion still showing a less
differentiated phenotype (10.5% HES1-positive and 36%
MLANA-positive). Epidermal PAX3-positive melanocytes show
a similar profile to those in the ORS (27.9% HES1-positive, 62%
MLANA-positive). Interestingly, there are a similar number of
MLANA-positive (but PAX3-negative) melanocytes in the epider-
mis (30.5%) and the hair matrix (40%), in contrast to the ORS
where such cells are rare (3.9%). PAX3 expression seems to
correlate with undifferentiated (co-expressing HES1 and MITF)
and differentiating (co-expressing MLANA and MITF) cells,
whereas it might be diminished in terminally differentiated cells
(PAX3-negative but MLANA or MITF-positive) that are further
along the continuum of differentiation. It is possible that PAX3 is
involved in maintenance of melanocyte ‘‘stemness’’, at least while
they are migrating towards their destination, either in the hair
follicle or the epidermis.
PAX3 in apoptosis
It is also very likely that PAX3 is involved in keeping
melanocytes alive, since three quarters of epidermal and more
than half ORS and matrix PAX3-positive melanocytes show
expression of the PAX3 target, antiapoptotic BCL2L1. PAX3 is
previously reported as an antiapoptotic regulator in tumours,
including melanoma [44–49]. Several known antiapoptotic
factors, such as tumour suppressors p53, PTEN and BCL2L1,
are involved in Pax3-induced cell survival [48,50,51]. BCL2L1 is
directly transcriptionally regulated by PAX3, and in rhabdomyo-
sarcoma treatment with PAX3 or BCL2L1 antisense oligonucleo-
tides, individually or in combination, decreases cell viability to a
similar extent, suggesting that they lie in the same antiapoptotic
pathway [51]. Similarly, BCL2L1 is associated with melanoma cell
survival, since its expression correlates with melanoma progression
[52,53] and treatment with antisense oligonucleotides resulted in
reduction of cell viability [54,55]. However, its expression is
observed in naevi and normal skin [52,53] and in melanocytes it
also affects cell viability [55].
As expected we have observed positive BCL2L2 staining in all
normal skin, naevi and primary melanoma samples analysed. The
majority of PAX3-positive cells in melanomas, naevi and normal
skin co-express BCL2L2 at a similar frequency. These results
support the potential role of PAX3 as one of many cell survival
regulators. The results also indicate that normal melanocytes
might utilise the same cell survival regulatory pathway as
melanoma cells, both in the epidermis and in hair follicles.
PAX3 in migration
The cell adhesion molecule MCAM has been associated with
melanoma progression and metastatic potential [56–59]. Even
though MCAM is frequently expressed in naevi [36] its increased
expression in melanomas shows significant correlation with poor
disease free survival and mortality [36,56–58,60,61]. Up-regula-
tion of MCAM, together with loss of keratinocyte-dependence, is
one of the crucial events that allows melanoma cells to invade the
dermis and progress to vertical growth phase (for review see [62]).
MCAM can mediate both homotypic adhesion between melano-
ma cells, promoting local tumour growth, and heterotypic
adhesion between melanoma cells and endothelial cells of blood
vessels, facilitating metastatic spread [59,63,64].
Pax3-transfected melanocyte cells show increased expression of
MCAM, both at an mRNA and protein level, suggesting that
MCAM is a downstream target of Pax3 [65,66]. Our results
confirm co-expression of PAX3 and MCAM in melanomas and
naevi, mainly in the cells that form nests located in the dermal
component of the lesion, with melanoma samples showing larger
numbers of PAX3, MCAM-positive cells compared to naevi. This
indicates that some PAX3-positive cells in naevi and melanomas
have the capability to undergo vertical spread/migration. It
suggests that regulation of migration might be one of the roles of
PAX3 in melanoma, as it is in development, where Pax3 regulates
cMet [67].
The frequent observation of MCAM expression in cells of the
hair follicle might be associated with downwards growth into the
dermis and migration of follicular cells. The observation that some
PAX3-positive melanocytes in the ORS show MCAM expression,
in contrast to those in the epidermis, suggests that MCAM is
associated with migration of normal melanocytes from the bulge
area to the developing hair follicle and to the epidermis. Upon
reaching the epidermis, MCAM expression is downregulated.
Alternatively, epidermal melanocytes do not arise and migrate
from the bulge, but rather arise from interfollicular melanocyte
stem cells, similar to those believed to maintain interfollicular
epidermal homeostasis [68–70]. Even though some epidermal
melanocytes resemble the transient amplifying melanocytic cells of
the hair follicle with respect to their differentiation status, they are
not thought to have the same migratory propensity.
In summary, in addition to detection in the majority of naevus
and melanoma cells, we conclusively show PAX3 expression in
melanocytes of normal skin. Epidermal PAX3-positive melano-
cytes, like follicular cells, exhibit a variable differentiation status;
the majority show a more mature phenotype, but a proportion
(around 20%) show a less differentiated and proliferative
phenotype. Moreover, these melanocytes frequently show expres-
sion of a cell survival marker. Our results suggest that a previously
identified role for PAX3, as a regulator of an undifferentiated
plastic state, may operate in melanocytes of normal skin. This role,
possibly required for cellular response to environmental stimuli,
may predispose a proportion of these cells to a successful
malignant transformation as they are antiapoptotic, undifferenti-
ated and proliferative.
In addition, our findings that PAX3 expression is specific for
both the melanocytic lineage and melanocytic lesions, could have
potential applications in the clinical setting, as an immunohisto-
chemical assay for the differential diagnosis of melanoma. The
effectiveness of the commercially available anti-PAX3 antibodies,
and optimisation of staining protocols shown in this paper, might
also prove useful in a clinical setting.
Materials and Methods
Sample collection
De-identified archival tissue samples were obtained from several
pathology laboratories in accordance with the Human Research
Ethics Committee of Edith Cowan University (ethics approval
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patient archival tissue samples. Samples were previously diagnosed
by certified pathologists. 4mm thick formalin fixed paraffin
embedded tissue sections were used for immunohistochemistry
and immunofluorescence. The following samples were analysed by
immunohistochemistry and immunofluorescence: 10 normal skins
(including 3 hairy, 2 limb and 2 breast skin samples, and 3 samples
had no anatomic location specified), 14 naevi (including 5
intradermal, 6 compound and 3 junctional samples), 15 primary
(including 8 superficial spreading melanoma samples, 2 of radial
growth phase, and 1 sample each of acral lentiginous, nodular,
neurotropic, recurrent and lentigo maligna melanoma) and 5
systemic melanoma metastases (2 small bowel and 3 lymph node).
Tissue samples characterized here as normal skins were free of any
melanocytic lesion, having been used for other diagnostic purposes
(solar keratosis, seborrhoeic keratosis and granulomatous follicu-
litis) or tissue obtained after breast reduction. Normal skin samples
originated mainly from limbs or face (referred to as sun-exposed
skin) or breast (referred to as reduced sun-exposed skin).
Additionally, a separate set of 12 archival samples, including 2
normal skin, 5 naevi and 5 primary melanomas as well as 5
cryopreserved lymph node melanoma metastases were analysed by
qRT-PCR.
RNA extraction and qRT-PCT
Total RNA was extracted from the paraffin embedded and
cryopreserved tissue samples using Aurum Total RNA Mini Kit
(Bio-Rad) according to the manufacturer’s recommendations.
Slight modifications were made to the protocol used for paraffin
embedded samples. Mainly, sections were dewaxed in Xylene and
absolute Ethanol (each twice for 10 minutes), before tissue was
scratched from the slides and lysed in a mixture of Tissue Lysis
Buffer (High Pure RNA Paraffin Kit, Roche), Proteinase K and
10% SDS by incubation at 55uC overnight.
The quality and integrity of extracted RNA was assessed by gel
electrophoresis and subsequent amplification of the housekeeping
gene GAPDH. 250ng of the total RNA was reverse transcribed
with Omniscript RT kit (Qiagen), according to the manufacturers’
instructions and PCR was performed using Taq DNA Polymerase
(Qiagen). Primers used were, for GAPDH:5 9-GGG TGT GAA
CCA TGA GAA GT-39 (forward) and 59-GAC TGT GGT CAT
GAG TCC T-39 (reverse) (Takeuchi et al. 2003); and for PAX3:5 9-
AGT GAG ATT ACG CGC TAG -39 (forward) and 59-CCA
GCG GAA GAC CAG AAA C-39 (reverse). Real time PCR was
performed using iQ SYBR Green Supermix (Bio-Rad). Each
sample was run in duplicate and assays included negative controls
(reagents without RNA or cDNA) and positive controls (plasmid
DNA containing a PAX3 insert). The calibration curve was
generated using the threshold cycle (Ct) of 8 serial dilutions of
plasmid DNA template with known copy number. The Ct value of
the sample was interpolated from the standard curve and mRNA
copy number, mean value and standard deviation were calculated
using iQ5 RealTime Detection System Software (Bio-Rad
Laboratories). The increase in the mean values of mRNA copy
number for each sample relative to that in the normal skin was
expressed as a fold-change increase in mRNA.
Antibodies
The following primary antibodies were used: mouse monoclonal
to PAX3 (DSHB, 1/10), rabbit polyclonal to PAX3 (Invitrogen, 1/
500), mouse monoclonal to MITF (Merck, 1/20), mouse
monoclonal to MLANA (Merck, 1/50), rabbit polyclonal to
HES1 (Abcam, 1/100), rabbit monoclonal to BCL2L1 (Abcam, 1/
50), rabbit monoclonal to MCAM (Abcam, 1/500) and rabbit
polyclonal to Ki67 (Abcam, 1/25). For immunofluorescent
staining the following secondary and tertiary antibodies were
used: anti-mouse conjugated AlexaFluor-488 (1/500), anti-rabbit
conjugated AlexaFluor-488 (1/500), anti-mouse conjugated Alex-
aFluor-546 (1/500), or biotinylated anti-rabbit IgG (1/500) linked
to streptavidin-conjugated AlexaFluor-546 (1/500). All antibodies
were diluted in PBST (0.2% TritonX-100 in PBS) together with
1%NGS for immunofluorescent staining.
Immunohistochemistry
Paraffin embedded sections were dewaxed in xylene (365 min-
utes) and dehydrated in ethanol series (365 minutes in 100%
ethanol, 1 minute in each of 95% and 70% ethanol, and 3610
dips in ddH20). Antigen retrieval was routinely performed in
EDTA/Tris, pH 8.0, by heating for 365 minutes in a microwave
oven, at approximately 750 Watts. Slides were left to cool to room
temperature for at least 20 minutes. Sections were washed in PBS
and endogenous peroxidases were blocked with 3% H202 for
10 minutes. After rinsing in PBS, sections were blocked with 10%
FCS for one hour, followed by incubation with primary
antibodies for one hour at room temperature. After washing in
PBS, the secondary antibody linked to biotin (Dako, LSAB kit)
was applied and sections were incubated for 20 minutes at room
temperature. After washing in PBS-Tween20 (0.05%), sections
were incubated with streptavidin conjugated horseradish perox-
idase (Dako, LSAB kit) for 20 minutes at room temperature,
washed in PBS-Tween20, then incubated with DAB (Dako) for
several minutes. The reaction was stopped by washing in ddH20,
and the signal was enhanced by applying a solution of CuSO4
and NaCl, for 3 minutes. Hematoxylin staining was performed
before the slides were mounted with DPX neutral mounting
medium. Results were analysed on an Olympus BX51 micro-
scope and images were captured using an Olympus DP71
camera. Controls with primary antibodies withheld were
immunonegative. The specific staining of nuclear markers
PAX3 and MITF was generally distinguishable from the
cytoplasmic melanin deposit in the tissue by their sub-cellular
localisation. Intensity of PAX3 staining was compared across all
samples analysed and described as either weak or strong.
Immunofluorescence
The same dewaxing, rehydration and antigen retrieval proce-
dures described above were followed for immunofluorescence.
Sections were blocked with 10%NGS for one hour at room
temperature, followed by incubation with primary antibodies at
4uC overnight (for rabbit PAX3 and MITF co-staining) or at room
temperature for one hour (for all other antibodies). After washing
in PBS, sections were incubated with the appropriate secondary
antibody (followed by tertiary only for rabbit PAX3 and HES1) for
one hour and washed in PBS. For counterstaining Hoechst 33342
was used. Sections were mounted with FluorSave Reagent
(Calbiochem) and analysed on an epifluorescent Olympus BX51
microscope equipped with an Olympus DP71 camera. Controls
with primary antibodies withheld were immunonegative. For each
sample, quantification of cells positive for a given marker was
performed by analysis of 5–10 representative regions of the
section. The number of double-labelled cells was calculated
relative to the number of cells positive for a comparative marker
and expressed as a percentage.
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